vs
Side-by-side financial comparison of Nuvation Bio Inc. (NUVB) and STEM, INC. (STEM). Click either name above to swap in a different company.
STEM, INC. is the larger business by last-quarter revenue ($47.1M vs $41.9M, roughly 1.1× Nuvation Bio Inc.). On growth, Nuvation Bio Inc. posted the faster year-over-year revenue change (633.1% vs -15.6%).
Nuvation Bio Inc. is a clinical-stage biopharmaceutical company focused on researching and developing targeted oncology therapies to address unmet medical needs in difficult-to-treat cancer types. Its core pipeline features novel drug candidates targeting key oncogenic pathways, with primary operations and market presence centered in North America.
StemCells, Inc. is a public biopharmaceutical company headquartered in Newark, California, that is developing purified human neural stem cells (HuCNS-SCs) in the hopes of treating central nervous system disorders and paralysis. StemCells' HuCNS-SCs have the ability to differentiate into the three main types of cells found in the central nervous system: neurons, astrocytes and oligodendrocytes.
NUVB vs STEM — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $41.9M | $47.1M |
| Net Profit | — | $-16.0M |
| Gross Margin | — | 48.9% |
| Operating Margin | -81.3% | -17.7% |
| Net Margin | — | -33.9% |
| Revenue YoY | 633.1% | -15.6% |
| Net Profit YoY | — | 68.8% |
| EPS (diluted) | $-0.11 | $-4.40 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $41.9M | $47.1M | ||
| Q3 25 | $13.1M | $38.2M | ||
| Q2 25 | — | $38.4M | ||
| Q1 25 | — | $32.5M | ||
| Q4 24 | $5.7M | $55.8M | ||
| Q3 24 | — | $29.3M | ||
| Q2 24 | — | $34.0M | ||
| Q1 24 | $0 | $25.5M |
| Q4 25 | — | $-16.0M | ||
| Q3 25 | $-55.8M | $-23.8M | ||
| Q2 25 | — | $202.5M | ||
| Q1 25 | — | $-25.0M | ||
| Q4 24 | — | $-51.1M | ||
| Q3 24 | — | $-148.3M | ||
| Q2 24 | — | $-582.3M | ||
| Q1 24 | $-14.8M | $-72.3M |
| Q4 25 | — | 48.9% | ||
| Q3 25 | 74.5% | 35.5% | ||
| Q2 25 | — | 33.4% | ||
| Q1 25 | — | 32.4% | ||
| Q4 24 | 26.2% | -4.4% | ||
| Q3 24 | — | 21.2% | ||
| Q2 24 | — | 27.6% | ||
| Q1 24 | — | -95.0% |
| Q4 25 | -81.3% | -17.7% | ||
| Q3 25 | -430.1% | -33.6% | ||
| Q2 25 | — | -34.8% | ||
| Q1 25 | — | -65.0% | ||
| Q4 24 | -944.5% | -84.4% | ||
| Q3 24 | — | -493.2% | ||
| Q2 24 | — | -1705.5% | ||
| Q1 24 | — | -267.0% |
| Q4 25 | — | -33.9% | ||
| Q3 25 | -425.2% | -62.2% | ||
| Q2 25 | — | 527.8% | ||
| Q1 25 | — | -76.9% | ||
| Q4 24 | — | -91.6% | ||
| Q3 24 | — | -506.3% | ||
| Q2 24 | — | -1712.6% | ||
| Q1 24 | — | -283.9% |
| Q4 25 | $-0.11 | $-4.40 | ||
| Q3 25 | $-0.16 | $-2.84 | ||
| Q2 25 | — | $-1.79 | ||
| Q1 25 | — | $-0.15 | ||
| Q4 24 | $0.00 | $-15.29 | ||
| Q3 24 | — | $-18.24 | ||
| Q2 24 | — | $-71.81 | ||
| Q1 24 | $-0.07 | $-0.46 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $529.2M | $48.9M |
| Total DebtLower is stronger | $47.2M | — |
| Stockholders' EquityBook value | $305.7M | $-249.4M |
| Total Assets | $594.8M | $308.9M |
| Debt / EquityLower = less leverage | 0.15× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $529.2M | $48.9M | ||
| Q3 25 | $549.0M | $43.1M | ||
| Q2 25 | — | $40.8M | ||
| Q1 25 | — | $58.6M | ||
| Q4 24 | $502.7M | $56.3M | ||
| Q3 24 | — | $75.4M | ||
| Q2 24 | — | $89.6M | ||
| Q1 24 | $597.0M | $112.8M |
| Q4 25 | $47.2M | — | ||
| Q3 25 | $47.1M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $305.7M | $-249.4M | ||
| Q3 25 | $325.9M | $-235.7M | ||
| Q2 25 | — | $-214.1M | ||
| Q1 25 | — | $-417.5M | ||
| Q4 24 | $463.8M | $-398.4M | ||
| Q3 24 | — | $-344.1M | ||
| Q2 24 | — | $-203.2M | ||
| Q1 24 | $594.0M | $371.6M |
| Q4 25 | $594.8M | $308.9M | ||
| Q3 25 | $601.6M | $362.6M | ||
| Q2 25 | — | $379.2M | ||
| Q1 25 | — | $405.1M | ||
| Q4 24 | $540.6M | $437.4M | ||
| Q3 24 | — | $537.8M | ||
| Q2 24 | — | $691.5M | ||
| Q1 24 | $613.1M | $1.3B |
| Q4 25 | 0.15× | — | ||
| Q3 25 | 0.14× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-29.7M | $8.2M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-29.7M | $8.2M | ||
| Q3 25 | $-52.9M | $11.4M | ||
| Q2 25 | — | $-21.3M | ||
| Q1 25 | — | $8.5M | ||
| Q4 24 | $-46.3M | $-14.7M | ||
| Q3 24 | — | $-9.4M | ||
| Q2 24 | — | $-11.9M | ||
| Q1 24 | $-15.7M | $-621.0K |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | -0.11× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
